Q BioMed Inc (OTCMKTS:QBIO) shares continue to act well amid a flurry of important catalysts. We covered the stock in a recent profile [HERE].
Among these catalysts now in play for the stock, we saw analysts at Brookline Capital Markets initiate coverage of the biotech accelerator firm with a ‘buy’ recommendation and a $16/share price target, which represents nearly a 10x upside from present levels.
In addition, the company just announced that Pamela Ventola Phd, from Yale University, has joined its Advisory Committee for its QBM-001 clinical program. QBM-001 is being developed and tested for the treatment of minimally verbal or non-verbal toddlers with an Autism Spectrum Disorder (ASD).
“Children with ASD need safe, effective and targeted treatments that are tested under conditions that take their best interests into consideration to ensure a successful trial,” explained Dr. Ventola. “I am inspired that Q BioMed has the same vision and am excited to ensure QBM-001 has the best chance to help their targeted subgroup.”
Autism Spectrum Disorder (ASD) is the fastest growing developmental disability and is diagnosed more frequently than AIDS, cancer, and diabetes combined, with 1 in 59 children now being diagnosed (CDC, 2018). With an annual growth rate of 10 – 17 %, this represents a problem of epidemic proportions.
Q BioMed Inc. (OTCMKTS: QBIO) is an interesting player in the small float small-cap biotech growth space that has projects in motion to attack a major growth market (non-verbal learning disorder) with little competition and big potential.
This is a biomedical acceleration and development company that focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies.
The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma.
Q BioMed Inc. has a partnership with Sphaera Pharma to develop an analog of QBM-001 for pediatric developmental nonverbal disorder; and a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001.
Q BioMed Inc (OTCMKTS:QBIO) has a strong balance sheet, with cash levels far exceeding current liabilities ($787K against $707K).
4,137 total views, 1 views today